Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studiesDavid T. Rubin, Patrick Chamouard, Jessica R. Allegretti et al.|The Lancet|2024Cited by 95
Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trialMillie Long, James Fon, Jessica R. Allegretti et al.|The Lancet. Gastroenterology & hepatology|2026Cited by 6
P520 Preferences towards treatment attributes among patients with Crohn’s disease and ulcerative colitis in Argentina, Australia, Brazil, Saudi Arabia and Taiwan: a discrete choice experimentMarjorie Argollo, Elenore Judy B. Uy, Yoon‐Kyo An et al.|Journal of Crohn s and Colitis|2024Cited by 1